Sanofi (SNY) Reports Positive Results in Phase 3 trial for Toujeo in Children & Adolescents with Type 1 Diabetes; CHMP Adopts Positive Opinion for Expanded Indication

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Sanofi (SNY) Reports Positive Results in Phase 3 trial for Toujeo in Children & Adolescents with Type 1 Diabetes; CHMP Adopts Positive Opinion for Expanded Indication

Barclays Reiterates Equalweight Rating on Sanofi (SAN:FP) (SNY)

November 4, 2019 2:49 AM EST

Barclays analyst Emmanuel Papdakis reiterated an Equalweight rating and EUR80.00 price target on Sanofi (SAN:FP) (NASDAQ: SNY).

... More

Sanofi (SNY) Reports Q3 EPS of EUR1.92

October 31, 2019 8:05 AM EDT

Sanofi (NASDAQ: SNY) reported Q3 EPS of EUR1.92. Revenue for the quarter came in at EUR9.5 billion versus the consensus estimate of EUR10.38 billion.

Third-quarter 2019 sales performance(3) led by Sanofi Genzyme and Emerging Markets

Net sales were 9,499 million, up 1.1% on a reported basis, down 1.1%(3) at CER and up 0.5% at CER/CS(4).Sanofi Genzyme sales increased 19.5% driven by continued strong uptake of Dupixent®.Vaccines sales decreased 9.8% reflecting anticipated weighting of U.S. flu vaccines supply towards fourth quarter.CHC sales up 0.4%, impacted by Zantac® voluntary... More